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Edited by Micheal R. BubbAbstract The multisubunit enzyme V-ATPase harbours iso-
forms of individual subunits. a3 is one of four 116 kDa subunit
a isoforms, and it is crucial for bone resorption. We used small
interfering RNA (siRNA) molecules to knock down a3 in rat
osteoclast cultures. Labeled siRNA-molecules entered osteo-
clasts via endocytosis and knocked down the a3 mRNA. Bone
resorption was decreased in siRNA-treated samples due to de-
creased acidiﬁcation and osteoclast inactivation. Expression of
a1 did not respond to decreased a3 levels, suggesting that a1 does
not compensate for a3 in osteoclast cultures. Subunit a3 is thus
an interesting target for novel nucleic acid therapy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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siRNA1. Introduction
Osteoclasts are large multinuclear cells specialized for
resorption of mineralized bone [1]. Actively resorbing osteo-
clasts are highly polarized cells with four specialized membrane
domains: ruﬄed border, sealing zone, functional secretory do-
main and basolateral membrane [2,3]. The low pH in the
resorption lacuna is maintained by ATP-consuming vacuolar
proton pumps (V-ATPase), which are present at the ruﬄed
border membrane [4,5]. V-ATPases are essential for osteoclas-
tic bone resorption, and V-ATPase inhibitors reduce bone
resorption in vitro and in vivo [6–8].
V-ATPases are multisubunit complexes including two func-
tional domains: a catalytic V1 sector and membrane-spanning
V0 sector where subunit a is located. Yeast V-ATPases contain
two diﬀerent isoforms of subunit a that diﬀer in their subcellu-
lar location, coupling eﬃciency and in vivo dissociation be-
tween V1 and V0 complexes [9]. In mouse and human, four
subunit a isoforms have been identiﬁed [10–13]. These isoforms
are diﬀerentially expressed in various tissues. Isoform a1 is
found in clathrin-coated vesicles, with highest expression in
brain and liver. Isoform a2 is expressed in heart, kidney, brain,
and liver. Isoform a3 is highly expressed in osteoclasts and dis-Abbreviations: siRNA, small interfering RNA; V-ATPase, vacuolar
H-ATPase; AO, acridine orange; TRACP, tartrate-resistant acid
phosphatase
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doi:10.1016/j.febslet.2005.07.078ruption of the mouse or human a3 gene results in severe oste-
opetrosis [14,15] including infantile malignant osteopetrosis
[16–18]. Isoform a4 is expressed in kidney intercalated cells,
where it is involved in the regulation of acid–base homeostasis.
The ﬁrst report describing the cloning of isoform a3 indi-
cated that this isoform was unique to the osteoclast and essen-
tial for osteoclast function [19]. Later, a3 was also detected in
other tissues [10,11], but the highest expression was still found
in bone [20]. In RAW267.4 cells that can be induced to form
multinuclear osteoclast-like cells, a3 expression is induced dur-
ing osteoclast diﬀerentiation. Subunit a3, but not a1 or a2, are
located in the ruﬄed border membrane of actively resorbing
osteoclasts [11,21]. Primary osteoclasts are hard to transfect
although macrophage cell lines stimulated to diﬀerentiate into
osteoclasts are transfectable with small interfering RNA (siR-
NA)-constructs [22–24]. The current paper describes for the
ﬁrst time carrier-free siRNA uptake into primary osteoclasts,
where downregulation of a3 by siRNA molecules critically im-
pairs bone resorption.2. Materials and Methods
2.1. Design and synthesis of siRNA molecules
Three siRNA molecules targeting rat a3 coding region were designed
according to Elbashir et al. [25] with Ambions design system
(www.ambion.com). The siRNA sequences shown in Table 1 were syn-
thesized from DNA templates with the Silencer siRNA construction
kit according to the suggested protocol (Ambion, USA). To analyze
uptake and intracellular distribution of siRNA molecules, Cy3 labeling
with Silencer siRNA labeling kit was used (Ambion, USA).
2.2. Cell culture and transfection
Cell culture reagents were obtained from Invitrogen (UK). Bone
cells isolated from rat long bones were cultured on glass coverslips
or bovine bone slices as described before [26]. 30 U of prime RNAse
inhibitor (Eppendorf, Germany) was added to each 300 lL of culture
medium 15 min before siRNA additions to inhibit RNAse activity in
the medium. All siRNA molecules were used at 100 nM concentra-
tions. Uptake of labeled siRNA-molecules into osteoclasts was moni-
tored in samples incubated with siRNA-duplexes at +4 C; control
samples were kept at room temperature. After 45 min, cells were
washed in PBS and transferred into fresh, warm culture medium.
Endocytosis of membrane-bound siRNA-molecules was allowed to
proceed for 0, 1, 2, 4 or 12 h prior to microscopical evaluation. The ef-
fects of siRNA-molecules on osteoclast cytoskeleton were monitored
by incubating cells in the presence of siRNA-molecules for 48 h, rinsed
and incubated in fresh medium for another 24 h.2.3. RNA extraction and RT-PCR
Total RNA was extracted from siRNA-treated cells using GenElute
mammalian total RNA kit (Sigma, USA) and genomic DNA was re-
moved with DNAse (Ambion, USA). Quantitative RT-PCR was per-
formed using the Opticon DNA Engine (MJ Research, USA) and
DyNAmo SYBR Green 2-step qRT-PCR system according to theblished by Elsevier B.V. All rights reserved.
Table 1
siRNA molecules targeted against NM 199089
Name Sequence (5–3)
siRNA-1 sense CAAGUUCUAUUCAGGGACCUU
siRNA-1 antisense GGUCCCUGAAUAGAACUUGUU
siRNA-2 sense UGGGACAGGAAUAAAAAGCUU
siRNA-2 antisense CUUUUUAUUCCUGUCCCAUU
siRNA-3 sense UAAAAAGCUGGCUGGCCCAUU
siRNA-3 antisense UGGGCCAGCCAGCUUUUUAUU
Scrambled control siRNA
Sense GCACCUAUGAGAGACUGACUU
Antisense UUGCCAUUAGCUGCAGCGUUU
Scrambled control siRNA has the same nucleotide composition as
siRNA-3, but lacks signiﬁcant sequence homology to known genes.
Table 2
Quantitative RT-PCR primers
Target primer sequence (50 ﬁ 30) Amplicon size (bp)
rat a1
L: ACGACCTCCAAATGGTTCTG 172
R: ACTTCTGCGATCAGGCACTT
rat a3
L: ATGAAGGCCGTGTACCTGAC 153
R: AGCCACAGCACTCACTCCTT
rat GAPDH
L: CAGCAATGCATCCTGCAC 101
R: TGGCATGGACTGTGGTCA
All primers were used at 0,5 lM concentrations and the annealing
temperature was +61 C.
Fig. 1. Uptake of CY3-labeled siRNA molecules (red) into rat
osteoclasts after 48 h. Cells were cultured on glass coverslips or bone,
and actin cytoskeleton was visualized with AlexaFluor488-phalloidin
(green). Transfection eﬃciency is shown as the percentage of Cy3-
positive osteoclasts of the total osteoclast number. Cy3-positive cells
shown in the insets were cultured on glass. Bar = 20 lm (n = 3).
Table 3
siRNA-uptake in samples incubated at room temperature or at +4 C
to block endocytosis
Plasma membrane
staining (% of
osteoclasts)
Intracellular vesicle
staining (% of
osteoclasts)
Cytoplasmic
staining (% of
osteoclasts)
RT with chase at +37 C
0 h 94 8 1
1 h 87 9 2
2 h 52 12 3
3 h 39 15 4
4 h 15 9 4
12 h 2 7 6
+4 C with chase at +37 C
0 h 97 0 0
1 h 85 0 0
2 h 73 1 0
3 h 68 1 1
4 h 50 4 3
12 h 11 5 3
Labeled siRNA ﬂuorescence was evaluated microscopically in 100
osteoclasts per sample group.
Fig. 2. Expression of subunit a isoforms a3 (A) and a1 (B) and
GAPDH was monitored by quantitative RT-PCR. Total RNA was
isolated from cells treated with siRNA molecules for 12 h, 24 h, 48 h or
72 h and equal amounts of total RNA was ampliﬁed with a1 or a3-
speciﬁc primers using SYBR green chemistry. Cycle thresholds (Ct)
were determined from the melting curves, and isoform a3 and a1
quantity was normalized with the GAPDH housekeeping gene. The
DCt (Ct target  CtGAPDH) values are shown in the Figure, indicating
that the higher the DCt value, the lower the target concentration was in
the original RNA sample.
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Fig. 3. (A) The number of osteoclasts was counted after TRACP-staining. TRACP-positive cells with at least three nuclei were counted as
osteoclasts. Cells were incubated with siRNA duplexes for 12, 24 or 48 h prior to ﬁxation and staining (n = 5). (B) The amount of normal and
disrupted actin rings was counted after phalloidin staining after a 48 h siRNA-treatment (left) or from samples treated with siRNA-molecules for
48 h followed by a 24 h incubation in siRNA-free medium (right). Normal actin rings were distinguished from disrupted actin rings on morphological
basis, as shown in the inset. Actin rings were counted from three bone slices for each sample group.
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shown in Table 2. Cycle tresholds (Ct) were determined and a1 and
a3 ﬂuorescence was normalized with the GAPDH reference gene
ﬂuorescence.
2.4. Stainings and microscopy
At given time points after siRNA treatment, cells were ﬁxed with 3%
paraformaldehyde–2% sucrose for 15 min. AlexaFluor488-phalloidin
was used to visualize actin and Hoechst was used to stain nuclei
(Molecular Probes, USA). Alternatively, cells were stained for tar-
trate-resistant acid phosphatase (TRACP) using Leukocyte acid
phosphatase kit (Sigma, USA) and osteoclasts were counted as
TRACP-positive cells with at least 3 nuclei. Intracellular vesicle acidi-
ﬁcation was followed in osteoclast cultures by acridine orange (AO,
Sigma, USA) uptake into live cells as described before [27]. Protein
level analysis were not possible due to a lack of suitable isoform aantibodies. Samples were viewed under a Leica TCS-SP confocal
microscope equipped with Argon-Crypton laser (Leica Microsystems
GmbH, Germany).
2.5. Osteoclast viability and activity
To monitor cell viability, Live/Dead-system was used according to
manufacturers protocol (Molecular Probes, USA). 0.8% sodium
azide-treated samples were included in the assay as a death control
group. Cells were incubated with dyes for 45 min, followed by ﬂuores-
cence intensity measurements using exitation/emission ﬁlter sets of 495/
520 nm (for Calcein AM) and 530/642 nm (for EthD). Viability indexes
were counted by dividing live cell ﬂuorescence by dead cell ﬂuores-
cence. Bone resorption was evaluated by counting WGA-lectin stained
resorption pits [28] and by measuring the C-terminal cross-linked
telopeptides of type I collagen (CTX) from culture medium with Cross-
Laps for culture kit (Nordic Biosciences, Denmark).
Fig. 4. Viability assay was performed on cells treated with siRNA-
molecules for 48 h. Calcein AM and EthD ﬂuorescence were measured
using appropriate band pass ﬁlters. Viability index was counted by
dividing Calcein AM ﬂuorescence with EthD ﬂuorescence. Sodium
azide was included as a cell death control. ***P < 0.001 (n = 4).
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for statistical analysis. Means and standard deviations (S.D.) were cal-
culated and are shown in Figures. P < 0.05 was considered statistically
signiﬁcant.Fig. 5. Acridine orange accumulation into acidic vesicles was moni-
tored after siRNA-treatment for 48 h. 5 nM Baﬁlomycin A1 was used
to inactivate V-ATPases. In neutral pH, AO is seen in green but in
acidic pH the color becomes red. Cells were cultured on glass
coverslips or bone. Multiple nuclei with typical green DNA-staining,
and acidic vesicles with intense red staining are seen in the control
osteoclasts, while no acidiﬁed compartments can be observed after
Baﬁlomycin treatment. Bar = 20 lm, n = 3.3. Results and discussion
To conﬁrm uptake of siRNA molecules into osteoclasts, up-
take of CY3-labeled siRNA molecules was followed. Both
inactive osteoclasts cultured on glass coverslips and resorbing
osteoclasts cultured on bone were positive for the CY3-labeled
siRNAs at all time points studied (Fig. 1). Labeled molecules
were seen in distinct intracellular vesicles and diﬀusely in the
cytoplasm. Best uptake eﬃciency was obtained with siRNA-
2 (14 ± 2.2% of all osteoclasts) and siRNA-3 (12 ± 1.1% of
all osteoclasts), while siRNA-1 was observed in only
8 ± 1.8% of all osteoclasts. Uptake and release of siRNA-mol-
ecules was also followed in cells where endocytosis was
blocked by keeping the samples at +4 C while treating the
cells with siRNA-molecules (Table 3). This resulted in accumu-
lation of labeled siRNA-molecules on the plasma membrane.
When unbound siRNA-molecules were washed away and
membrane-bound siRNA-molecules were allowed to be inter-
nalized by incubating the samples at +37 C, labeled siRNA-
molecules accumulated into intracellular vesicles. Labeled
siRNA-molecules were time-dependently released to the cyto-
plasm, where a veil-like staining could be observed. At least
a part of the siRNA-molecules were endocytosed by osteo-
clasts. Although the process was slow, the continuous low
uptake seemed to be enough to account for the physiological
responses seen in the cultures.
To monitor knockdown eﬀectivity and speciﬁcity, mRNA
levels were monitored with quantitative RT-PCR. Analysis
of RNA samples isolated from cells treated with siRNA mol-
ecules resulted in the ampliﬁcation of the expected products
for rat a3 and a1 (Fig. 2). Decreased a3 mRNA levels were ob-
served already 12 h after siRNA-2 treatment and 48 h aftersiRNA-1 and siRNA-3 treatment. The best knockdown eﬀect
was achieved with siRNA-2. No changes in a1 expression were
found at the time points studied with any of our siRNA-du-
plexes, showing the speciﬁcity of the a3 siRNA-duplexes in
knocking down isoform a3 but having no eﬀect on a1. Isoform
a3 is not exclusively osteoclast-speciﬁc and expression has been
observed in a variety of tissues; mostly in liver with decreasing
amounts in kidney, brain, lung, spleen, and muscle [10,11,21].
Mutations in the a3 gene cause, however, only bone pheno-
Fig. 6. Bone resorption activity in osteoclast cultures treated with
siRNA-duplexes was determined after 12, 24 or 48 h. Baﬁlomycin A1
was used at a 5 nM concentration to inhibit V-ATPases. (A)
Resorption pits were counted after WGA-lectin staining and (B)
CTX was measured from the culture media. *P < 0.05; **P < 0.01;
***P < 0.001 (n = 4).
Y. Hu et al. / FEBS Letters 579 (2005) 4937–4942 4941types. A possible explanation may be that other isoforms can
compensate for the lack of a3 in other tissues. Yeast V-ATP-
ases have two isoforms of subunit a: Vph1p and Stv1p. It
has been shown that Stv1p can partly compensate for the lack
of Vph1p when it was disrupted, leading to a less severe phe-
notype [29,30]. However, our data suggest that isoform a1 can-
not signiﬁcantly compensate for the reduced level of a3 in the
osteoclast cultures.
The eﬀects of siRNA duplexes on osteoclast number, as
determined by counting TRACP-positive multinuclear cells,
are shown in Fig. 3A. The number of osteoclasts remained un-
changed in siRNA-treated and control cultures and no signs of
induced apoptosis or decreased viability (Fig. 4) were ob-
served. Actively resorbing osteoclasts can be distinguished by
their actin ring structures [31]. As can be seen from Fig. 3B,
osteoclasts treated with siRNA-molecules became inactivated
and lost their actin rings, but the cells remained attached to
the bone surface. When cells were ﬁrst treated with siRNA-
molecules for 48 h and then cultured in fresh medium for an-
other 24 h, osteoclasts became activated and actin rings could
again be seen. This is in good agreement with recent data from
Karsdal et al. [32] who showed that osteoclast survival is in-
creased when acidiﬁcation is blocked. The increase in the num-
ber of inactive osteoclasts after siRNA-treatment without signs
of apoptosis induction might reﬂect the survival eﬀect de-
scribed before.
During acidiﬁcation of the resorption lacuna, V-ATPases
are ﬁrst transferred from intracellular vesicles to the ruﬄed
border membrane, through which protons are then trans-
ported to the extracellular resorption site. In non-resorbing
cells V-ATPases remain in the cytoplasmic vesicles which are
acidic. The physiological eﬀects of a3 knockdown were studied
by monitoring changes in intravesicular acidiﬁcation and in
bone resorption capacity. AO is a weak base that accumulates
into acidic compartments [33]. When present at high concen-
trations, it forms complexes resulting in a shift in ﬂuorescence
from green to red. As can be seen from Fig. 5, 5 nM Baﬁlomy-
cin A1 inhibited acidiﬁcation in all cells, resulting in the neu-
tralization of the intracellular compartments. After 48 h, all
siRNA molecules inhibited AO accumulation, with the most
signiﬁcant inhibition obtained with siRNA-3. The observed
diﬀerences in acidiﬁcation knockdown in non-resorbing and
resorbing osteoclasts show the importance of the physiological
substrate in this type of studies.
The ultimate test for osteoclast function is their capacity to
resorb bone. Upregulation of a3 expression has been detected
during osteoclast diﬀerentiation and mutations in the a3 gene
cause osteopetrosis in humans and in mouse [14–18]. These
data show that a3 isoform plays a key role in osteoclast phys-
iology. When the siRNA-eﬀects on bone resorption were stud-
ied by counting the number of resorption pits (Fig. 6A) or by
measuring the release of CTX-fragments into culture media
(Fig. 6B), resorption was signiﬁcantly decreased with 5 nM
Baﬁlomycin A1 and in samples treated with siRNA-2 and siR-
NA-3 for 48 h. Resorption pit depths remained unchanged
when analyzed at 48 h (6.4 ± 2.1 lm in siRNA-1 samples,
5.9 ± 2.7 lm in siRNA-2 samples, 7.2 ± 1.9 lm in siRNA-3
samples and 6.7 ± 2.6 lm in control samples, n = 3).
Osteoclasts seem to endocytose small amounts of siRNA-
molecules from the culture medium at individual speed. We
have previously shown that antisense-molecules are spontane-
ously taken up into primary osteoclasts [34,35] and metacarpaltissue cultures [36]. The current data show that siRNA-treated
primary osteoclasts did not die but lost their capacity to resorb
bone. Despite the seemingly low transfection rate, primary
osteoclasts respond to carrier-free siRNA-molecules and sug-
gest that novel gene knockdown tools can be useful also with
hard-to-transfect cells.
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